Literature DB >> 17362320

Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis.

V M Chia1, P A Newcomb, A Trentham-Dietz, J M Hampton.   

Abstract

Endogenous and exogenous sources of estrogen and characteristics altering these hormone levels have been related to endometrial cancer risk; however, their relationship to survival following diagnosis is less clear. In a population-based study, we examined whether mortality after endometrial cancer diagnosis was affected by prediagnosis obesity, diabetes, smoking, oral contraceptive use, parity, or postmenopausal hormone (PMH) use. Eligible women, aged 40-79 years, diagnosed from 1991-1994 with incident invasive endometrial cancer and identified through the Wisconsin statewide mandatory cancer registry were invited to participate. Of 745 eligible cases, 166 women were deceased after 9.3 years of follow-up, with 43 attributable to endometrial cancer, based upon vital records linkage. Hazard rate ratios (HRR) and 95% confidence intervals were adjusted for age at diagnosis, menopausal status, stage of disease, and other exposures of interest. Obese women (body mass index [BMI] >or=30 kg/m(2)) prior to endometrial cancer diagnosis had an increased risk of both all-cause (HRR=1.6, 95% CI 1.0-2.5) and endometrial cancer (HRR=2.0, 95% CI 0.8-5.1) mortality, compared with nonoverweight women (BMI<25 kg/m(2)). Endometrial cancer cases with diabetes also had an increased risk of all-cause mortality compared with nondiabetic women (HRR=1.7, 95% CI 1.1-2.5), although there was no association with endometrial cancer mortality. There were no associations between PMH use, oral contraceptive use, parity, or smoking and mortality from any cause. The results suggest that history of obesity and diabetes may increase risk of mortality after endometrial cancer diagnosis; modification of these characteristics may improve survival after endometrial cancer diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17362320     DOI: 10.1111/j.1525-1438.2007.00790.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  38 in total

Review 1.  Adipokines as novel biomarkers and regulators of the metabolic syndrome.

Authors:  Yingfeng Deng; Philipp E Scherer
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

2.  Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Authors:  Joshua Kilgore; Amanda L Jackson; Leslie H Clark; Hui Guo; Lu Zhang; Hannah M Jones; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

3.  Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons Learned.

Authors:  Alexander R Lucas; Brian C Focht; David E Cohn; Maryanna D Klatt; Janet Buckworth
Journal:  J Cancer Educ       Date:  2018-08       Impact factor: 2.037

4.  Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients.

Authors:  Hannah Arem; Yikyung Park; Colleen Pelser; Rachel Ballard-Barbash; Melinda L Irwin; Albert Hollenbeck; Gretchen L Gierach; Louise A Brinton; Ruth M Pfeiffer; Charles E Matthews
Journal:  J Natl Cancer Inst       Date:  2013-01-07       Impact factor: 13.506

5.  Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.

Authors:  Hui Guo; Weimin Kong; Lu Zhang; Jianjun Han; Leslie H Clark; Yajie Yin; Ziwei Fang; Wenchuan Sun; Jiandong Wang; Timothy P Gilliam; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 6.  Obesity and endometrial cancer survival: a systematic review.

Authors:  H Arem; M L Irwin
Journal:  Int J Obes (Lond)       Date:  2012-06-19       Impact factor: 5.095

Review 7.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

8.  Glucose metabolism disorders in cancer patients in a Chinese population.

Authors:  Ya-Shi Zhan; Lie Feng; Shao-Hui Tang; Wan-Geng Li; Meng Xu; Tian-Fu Liu; You-Fen Zhou; Yu-Lin Ma; Yun Zhang; Xian-Ming Pu
Journal:  Med Oncol       Date:  2009-03-05       Impact factor: 3.064

9.  Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Authors:  Leigh A Cantrell; Chunxiao Zhou; Alberto Mendivil; Kimberly M Malloy; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-10-12       Impact factor: 5.482

10.  Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites.

Authors:  Linda S Cook; Harold E Nelson; Myles Cockburn; Sara H Olson; Carolyn Y Muller; Charles L Wiggins
Journal:  Cancer Causes Control       Date:  2012-10-30       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.